公开(公告)号：EP2811018A1

公开(公告)日：2014-12-10

申请号：EP13743114.4

申请日：2013-02-01

申请人： Shionogi & Co., Ltd.

发明人： TAKAHASHI, Tatsuya ,  ONODA, Junji ,  YOSHIDA, Yasunobu ,  YAMANE, Shoji ,  NISHITOMI, Kouhei ,  YAMAKAWA, Hidekuni ,  YAMAUCHI, Akira ,  MORITA, Atsushi ,  FUKUDA, Isao

IPC分类号： C12N15/09 ,  C07K16/18 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  C12P21/08

CPC分类号： G01N33/6896 ,  C07K16/18 ,  C07K2317/30 ,  C07K2317/565 ,  G01N2333/47 ,  G01N2333/4709 ,  G01N2333/96475 ,  G01N2500/00 ,  G01N2800/28

摘要： Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP β or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPPβ contained in a biological sample.

摘要翻译： 本发明提供能够特异性识别sAPPβ的特定区域的单克隆抗体或所述抗体的片段，以及使用该单克隆抗体的测定方法和测定试剂盒，以准确测定生物样品中所含的sAPPβ。

公开(公告)号：EP2811018B1

公开(公告)日：2017-03-22

申请号：EP13743114.4

申请日：2013-02-01

申请人： Shionogi & Co., Ltd.

发明人： TAKAHASHI, Tatsuya ,  ONODA, Junji ,  YOSHIDA, Yasunobu ,  YAMANE, Shoji ,  NISHITOMI, Kouhei ,  YAMAKAWA, Hidekuni ,  YAMAUCHI, Akira ,  MORITA, Atsushi ,  FUKUDA, Isao

IPC分类号： C12N15/09 ,  C07K16/18 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  C12P21/08

CPC分类号： G01N33/6896 ,  C07K16/18 ,  C07K2317/30 ,  C07K2317/565 ,  G01N2333/47 ,  G01N2333/4709 ,  G01N2333/96475 ,  G01N2500/00 ,  G01N2800/28

公开(公告)号：EP4434520A1

公开(公告)日：2024-09-25

申请号：EP22895692.6

申请日：2022-11-18

申请人： Shionogi & Co., Ltd.

发明人： YOSHIDA, Yasunobu ,  UNO USUI, Mai ,  SHIMAZAKI, Atsuyuki ,  YUKIOKA, Hideo ,  KASHIWAGI, Yuto ,  YAMADA, Tomomi

IPC分类号： A61K31/4184 ,  A61P3/06 ,  A61P3/10 ,  A61P7/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  A61P13/12 ,  A61P21/00 ,  A61P43/00

CPC分类号： A61P9/04 ,  A61P43/00 ,  A61P7/00 ,  A61P9/00 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P21/00 ,  A61P3/06 ,  A61K31/4184 ,  A61P9/06

摘要： Provided is a pharmaceutical composition for treating and/or preventing at least one of heart diseases, heart disease complications, skeletal muscle diseases, and skeletal muscle conditions, the pharmaceutical composition having an excellent ACC2-selective inhibitory effect and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.
A pharmaceutical composition for treating and/or preventing at least one of heart diseases, heart disease complications, skeletal muscle diseases, and skeletal muscle conditions, the pharmaceutical composition comprising a compound represented by Formula (I):

wherein R1 is haloalkyl or non-aromatic carbocyclyl,
R2 is a hydrogen atom or halogen,
R3 is halogen,
ring A is a group represented by the formula:
-L1- is -O-(CH2)-, -(CH2)2-, or the like,
R4 is alkyl or haloalkyl, and
R5 is alkylcarbonyl or carbamoyl,
or a pharmaceutically acceptable salt thereof.